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Immunotherapy of cancer must promote antitumor eﬀector cells for tumor eradication as well as counteract immunoregulatory
mechanisms which inhibit eﬀectors. Immunologic therapies of cancer are showing promise, including dendritic cell-(DC-) based
strategies. DC are highly malleable antigen-presenting cells which can promote potent antitumor immunity as well as tolerance,
dependingontheenvironmentalsignalsreceived. Previously,wetestedapeptide-pulsedDCvaccinetopromoteAlpha-fetoprotein
(AFP-)speciﬁcanti-tumorimmunityinpatientswithhepatocellularcarcinoma(HCC),andreportedontheCD8+ Tcellresponses
induced by this vaccine and the clinical trial results. Here, we show that the peptide-loaded DC enhanced NK cell activation and
decreased regulatory T cells (Treg) frequencies in vaccinated HCC patients. We also extend these data by testing several forms of
DC vaccines in vitro to determine the impact of antigen loading and maturation signals on both NK cells and Treg from healthy
donors and HCC patients.
1.Introduction
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer mortality worldwide [1]. It often follows cirrhosis
caused by viral or alcoholic hepatitis. Prognosis remains
very poor, and treatment options are few [1]. Curative
surgery and liver transplantation are only available to a
small minority of early-stage HCC patients. Other common
therapies (including ablative therapies and Sorafenib) are
largely palliative. Treatment is complicated by preexisting
cirrhosis, as chemotherapy or resection may not be options
in a patient with poor liver reserves.
Alpha-fetoprotein (AFP) is an oncofetal antigen that is
expressed by more than half of HCC tumors and detectable
at elevated levels in the blood and tumor microenvironment
in these HCC patients [2]. AFP serves as the most common
serum biomarker for HCC and, as it is from undetectable to
10ng/mL in healthy adults [3], has also been identiﬁed as a
speciﬁc tumor-associated antigen for HCC immunotherapy
[4].WeandothershaveinvestigatedAFPasatumorrejection
antigen for immunotherapy of HCC [5–13].
Dendritic cell (DC) vaccines are promising vehicles for
activating antitumor speciﬁc T cells and NK cells for tumor
immunotherapy. They are immunologic sentinels which can
induce antigen-speciﬁc immunity or tolerance [14, 15]. DC
can be activated or matured with cytokines and toll-like
receptor (TLR) agonists such as interferon gamma (IFNγ)
or lipopolysaccharide (LPS) [16–19]. Antigen loading of DC
can be achieved in a number of ways, including peptide
pulsing, whole protein loading, and genetic engineering via
viral transduction.
While DC are critical to induction of immunity, other
immune cells are important as eﬀectors and regulators in
cancer immunity. CD56+CD16+/− natural killer (NK) cells
are the eﬀectors of the innate immune system that are able to
directly kill tumor or virally infected cells with reduced levels
of MHC class I molecules or that overexpress stress-induced
activating cell surface molecules (e.g., MICA/B recognition
via NKG2D), and that otherwise may escape immune
detection. Hepatic lymphocytes are enriched (up to 30%)
in NK cells that may play a role in antitumor defense [20].2 Clinical and Developmental Immunology
Table 1: HCC patient demographics.
Pt. Dose
DC
Risk
Factor Stage Previous treatments1 Pre-AFP
(ng/mL)
Post-AFP
(ng/mL) Response2 PFS3
(mo)
OS4
(mo)
A1 1 × 106 ?I V b
Chemoembo, CDDP,
Adriamycin, 5-FU, Xeloda,
Thalidomide
2.811 2.748 (+28) PD 0 4
A2 1 × 106 HBV IVa Chemoembo 4.740 5.770
(d + 28) PD 0 20
A35 1 × 106 EtOH IVa RFA 3.080 (no DC) (no DC) 0 2
A46 1 × 106 HCV IVb — 10,800 10.650 (1 vaccine) 0 —
B2 1 × 106 ? IVa Surgery 5.100 7.650
(d + 35) PD 0 4
B37 5 × 106 HCV IVa Chemoembo RFA 102 65
(d + 28) NE 0 35
B5 5 × 106 HBV IVa Chemoembo, CarboTaxol,
Xeloda 1.630 2.515
(d + 112) PD 0 3+
B8 5 × 106 HCV IVb Chemoembo 96.7 134 PD 0 5+
1Previous treatments received (chemoembo, chemoembolization; CDDP, cis-platin; 5-FU, 5-ﬂouro-uracil; Xeloda, capecitabine; RFA, radiofrequency
ablation; carbo, carboplatin; XRT, radiation therapy).
2PD: progressive disease, NE: no evidence of disease.
3PFS: progression free survival.
4OS: overall survival.
5No DC: no DC vaccines could be generated which passed clinical protocol release criteria.
61 vaccine: patient progressed early and did not receive the 3DC vaccinations.
7NE: patient B3 responded to chemoembolization and RFA and was vaccinated shortly thereafter, and had 35mo. OS.
Murine models support a role for NK cell eﬀectors in liver
tumor responses. In mice, antitumor eﬀects mediated by NK
cells were IFN-γ dependent [21]. The CD4+CD25hiFOXP3+
T regulatory (Treg) cell has more recently been recognized
as an important target in immunotherapy because of its role
in inhibiting the immune response. Patients with HCC have
been shown to have defects in NK cell function [22]an dh i gh
intratumoral [23] and circulating levels of Treg [24], all of
which may impact the progression of this disease.
We previously tested an AFP peptide-pulsed DC vaccine
in a phase I clinical trial. The vaccine was found to be safe
and immunogenic in late-stage HCC patients [25–27]. We
detectedtypeIimmunityinducedtothe4immunizingHLA-
A∗0201-restricted AFP-derived peptides in the majority of
patientsbyIFN-γ ELISPOTandMHCclassItetramerassays.
It has been demonstrated that DC and NK cells are
capable of interacting with and activating each other [28–
30]. We have found that recombinant adenovirus (AdV)-
transducedDC(AdV/DC),unlikeimmatureDC,arecapable
of functionally activating NK cells [17]. There are also
circumstances in which DC can promote Treg expansion. In
this study, we examined the in vivo eﬀects of AFP peptide-
pulsed DC on NK cell activation and Treg frequencies
and phenotypes in peripheral blood mononuclear cells
(PBMC) of HCC patients and described evidence for both
NK cell activation and decreased frequencies of FOXP3+
Treg cells. We then compared several clinically relevant DC
preparations for eﬀects on NK cells and Treg in vitro and
ﬁnd diﬀerences in the DC groups and between HCC patients
and healthy donors (HD). We show that AdV/DC, with
(pmAdV/DC) or without maturation, are most successful at
inducing NK cell activation and Treg depletion. The results
have relevance for the design DC-based vaccines in patients
with HCC.
2.MaterialsandMethods
2.1. Patient and Healthy Donor Cells. PBMC were obtained
from healthy volunteers (HD) and from HCC patients
enrolled in a peptide-pulsed DC vaccine (UCLA IRB #00-
01-026, IND BB9395; UPCI #04-001 and #04-111; informed
consent was obtained from all patients and donors). The
clinical trial was previously published in detail [26]w h i c h
included immunologic monitoring of vaccine responses
from banked PBMC. Limited patient data is listed in Table 1.
PBMC were isolated using a Ficoll gradient and either
tested fresh (some HD) or were cryopreserved (some HD
and all HCC patient cells) in RPMI1640/20% human AB
serum/10% DMSO for later testing.
2.2. Flow Cytometry. Cells were stained according to manu-
facturer recommendations, ﬁxed in 0.5% paraformaldehyde,
and analyzed on an CyAn high-speed analyzer (Dako,
Carpinteria, Calif) (UPCI Flow Cytometry Facility) and the
Summit v4.3 software within four days. NK cell phenotype
was investigated using: CD8 PE, CD16 ECD, CD3 APC
(Beckman Coulter), granzyme B FITC, CD25 PE-Cy7, CD56
PE-Cy5, and CD69 APC-Cy7 (BD Pharmingen). Treg were
investigated using: CD4 FITC, FOXP3 PE, and CD25 APC
(eBioscience) and reported as either the FOXP3 positive per-
centage or the MFI of FOXP3 expression in the CD4+CD25+
cells.Clinical and Developmental Immunology 3
2.3. Cell Isolation, DC Growth, and Vaccine Models (See
Figure 1). CD56+ NK cells and CD4+ T cells were isolated
from PBMC (Miltenyi Biotech) according to the manufac-
turer’s directions (CD56 beads, NK isolation kit, CD4+ Tc e l l
isolation kit). Change in MFI was considered “positive” if the
increase was ≥25% of the baseline MFI. Percent positivity
was considered positive if ≥5% greater than baseline.
Monocytes were isolated from PBMC using adherence
to T75 ﬂasks (Costar). They were cultured for 6-7 days in
RPM1640/5% human AB serum/PennStrep medium with
500U/mL IL-4 and 800U/mL GM-CSF (Schering-Plough,
K e n i l w o r t h ,N J ;A m g e n ,T h o u s a n dO a k e s ,C a l i f)t op r o m o t e
diﬀerentiation to myeloid DC.
After culture, DC were harvested, counted (Trypan Blue
Stain; BioWhittaker, Walkersville, MD), and cultured as
described below. DC were subsequently cocultured with NK
cells or T cells isolated from the autologous donor and
incubated 24hr (NK and CD4) to 5 days (CD4) at ratios of
1DC to 1–10NK or T cells. After the coculture, cells were
harvested, supernatant was collected and stored at −80◦C,
andcellswereanalyzedbyﬂowcytometryasdescribedabove.
Forpeptide-pulsedDC(pep/DC),DCwerepulsedwith1
or 2 speciﬁc AFP peptides (AFP158 FMNKFIYEI and AFP542
GVALQTMKQ; synthesized at the University Pittsburgh
Peptide Synthesis Facility) at 10μg/mL for 2hr at 37◦C,
then washed in medium before further culture. Similarly, for
protein-pulsed DC (prot/DC), DC were loaded with cord
blood-derived hAFP protein (CalBiochem) at 10μg/mL for
2hrat37 ◦C, then washed.
For AdV-transduced DC (AdV/DC), DC were trans-
duced for 2hr at 37◦C in serum-free media (IMDM) at
MOI = 1,000 with an AdV encoding full length AFP protein
(AdVhAFP) [5] and then washed in medium before further
culture. In the case of “prematured” AdV-transduced DC
(pmAdV/DC), DC were ﬁrst matured 24hr with 250ng/mL
LPS (Sigma) and 1000U/mL IFN-γ (Pepro Tech), after
which they were washed and transduced with AdVhAFP as
described above.
2.4. Luminex. Cell-free supernatants were collected from
cultures and frozen at −80◦C. They were subsequently
thawed and simultaneously analyzed with the multiplex
Luminex assay (Invitrogen) per manufacturer’s protocol in
a BioRad reader (UPCI Immunologic Monitoring Labora-
tory). The following analytes were tested: GM-CSF, IFN-γ,
IP-10, MCP-1, TNF-α,I L - 1 β,I L - 2 ,I L - 4 ,I L - 5 ,I L - 6 ,I L - 8 ,a n d
IL-10 in a kit pretested for any potential crossreactivity by
the manufacturer. Controls included the included standard
curve and multiplex QC standards (R&D Systems).
2.5. Statistical Analysis. One-tail t-test analyses were used
to estimate statistical signiﬁcance of diﬀerences obtained; P
values ≤0.05 were considered to be statistically signiﬁcant.
3. Results
Basedonourpreviousstudy(17),wehypothesizedthatHCC
patientsvaccinatedwithimmatureDCpulsedwithAFPpep-
tides (pep/DC) would not impact activation of circulating
NK cells. We assessed this by evaluating upregulation of
CD69orCD25activationmarkersonCD56hi/CD16− and/or
CD56lo/CD16+ NK cell subsets. We also wished to determine
whether Treg frequency (as determined by a change in
FOXP3-expressing CD4+CD25hi T cells) was modulated by
vaccination, which might also include changes in CTLA-4
[31, 32] or CCR7 [33] expression on Treg.
3.1. HCC Patients Treated with AFP Peptide-Pulsed DC
Exhibit Elevated Levels of NK Cell Activation. We tested
banked PBMC samples from ﬁve HCC patients, isolated
at diﬀerent time points during vaccination with AFP
pep/DC. Cells were stained immediately after thawing to
assess phenotype by ﬂow cytometry (see analysis strategy
shown in Supplemental Figure 1 in Supplementary Material
available online at doi:10.1155/2011/249281). Contrary to
our hypothesis, both regulatory CD56hiCD16− and cyto-
toxic CD56loCD16+ NK cells demonstrated activation post-
pep/DC vaccination, compared to baseline. Activation was
determinedbybothanincreaseinpopulationMFI(Figure1)
as well as percent positivity for CD25 or CD69 (Supple-
mental Figure 2). CD69 expression was increased in 4/5
patients for both CD56loCD16+ and CD56hiCD16− NK cells
according to MFI and percent positive values (Figure 1 and
Supplemental Figure 2). CD25 expression was also increased
by percent positivity and MFI in 3/5 and 4/5 patients’
CD56loCD16+ NK cells (Figure 1). For CD56hi NK cells,
CD25 was increased in 4/5 patients by MFI only. Patient B2
(CD56loCD16+CD69 percentage and CD56hiCD16−CD69
MFI) and B8 (CD56loCD16+CD69 and CD25 by both MFI
andpercentage)hadadecreaseinNKcellactivationafterﬁrst
vaccination, with an increase after second immunization.
The other patients displayed stronger NK cell activation. Of
the two main NK cell subsets, CD56loCD16+ cells showed
the greater degree of activation. Patients A1, A4, and B5,
with multiple time point samples available, had highest
NK cell activation after the ﬁrst round of vaccination, with
subsequenttimepointsshowinglessactivation.Additionally,
we tested these cells for the expression of NKG2D, an NK cell
activating receptor; however only low levels of this molecule
were detected on a small percentage of circulating NK cells
(data not shown).
3.2. HCC Patients Treated with AFP Peptide-Pulsed DC
Vaccines Display Decreased Frequencies of Circulating Treg
Cells. To examine Treg cell frequencies, CD3+CD4+ Tc e l l s
were gated on CD25hi or total CD25+ and intracellularly
stained for FOXP3. The Treg lymphocyte frequencies were
then assessed by ﬂow cytometry. FOXP3 expression in
the CD3+CD4+CD25hi T cells showed a consistent change,
decreasing overall in 4/5 of the patients tested, by both
percent positivity and MFI (Figure 2). Similar to the NK
cell activation measures, patient B2 also showed inferior
Treg changes by either measure. Treg frequencies slightly
increased in this patient after second and third immuniza-
tions. CD3+CD4+CD25hi cell surface CCR7 and CTLA-4
showed minor variation over time and were not considered
informative in our data set (data not shown).4 Clinical and Developmental Immunology
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Figure 1: CD69 and CD25 expression on CD56loCD16+ and CD56hiCD16− NK cells. Phenotyping of NK cells from patients who received
the AFP pep/DC vaccine, showing longitudinal changes. “Pre” denotes PBMC from time point 0. DC vaccines were delivered (after blood
draws) on days 0, 14, and 28. “Post” denotes PBMC from postvaccine administration at time points available in the remaining batched
PBMC. Patient A1 tested at days 35 and 56 (7 days and 28 days after the third vaccine); pt B2 at d28, 56, and 112; pt B5 at d14 and 28;
pt B8 and d14 and 112, pt A4 at d14. CD69 and CD25 markers (by MFI) are shown for both NK cell subsets. Percent positivity is shown
in Supplementary Figure 2. One-tail t-test P values are: CD56loCD16+CD69 MFI: pre to post 1: 0.05; pre to post 2: 0.03; post 1 to post
2: 0.16; all other values higher and not signiﬁcant (n.s.). CD56hiCD16−CD69 MFI: pre to post 1: 0.07, all other values higher and n.s.
CD56loCD16+CD25 MFI: pre to post 1: 0.05, pre to post 2: 0.11, post 1 to post 2: 0.12, all other values higher and n.s. CD56loCD16−CD25
MFI: pre to post 1: 0.04, pre to post 2: 0.15, all other values higher and n.s.
3.3. PhenotypicChanges in DC withDiﬀerentAntigenLoading
Strategies. The AFP peptide-pulsed DC did not undergo a
speciﬁc maturation step during vaccine preparation. Mat-
uration cocktails can impact surface levels of MHC class
I and II, costimulatory molecule levels, and cytokine pro-
duction. We hypothesized that diﬀerent DC antigen-loading
strategies, some of which impact DC maturation, would
result in unique phenotypic changes in the DC that would
impact activation and frequencies of other immune cells
(like NK cells and Treg) they interacted with. We previously
tested AdV-mediated genetic engineering of DC to enable
expression of full length antigens in DC [6, 34–37], and
found that AdV transduction promotes partial maturation
of DC and superior antigen-speciﬁc T cell responses. Since
we have identiﬁed AFP as a tumor-associated T cell antigen
for HCC [5, 10], we utilized the AFP antigen in multiple
forms (AdVhAFP, AFP protein, AFP-derived peptide) for
DC loading. We transduced HD DC with AdVhAFP and
compared them to immature DC (iDC) and LPS/IFN-γ-
m a t u r e dD C( m D C ) .D Cg r o u p sw e r et h e nc o c u l t u r e dw i t h
autologous NK or CD4+ T cells to determine the impact
on these lymphocytes. We examined CD83, CCR7, CD86,
and CD80 as markers of DC maturation. We found that
all four markers were upregulated after AdV transduction
as compared to iDC, but that their greatest upregulation
w a so b s e r v e di nm D C( d a t an o ts h o w n ,s i m i l a rt o[ 19,
37]). We also found that coculture with resting NK cells
modestly improved the expression of these DC maturation
markers in comparison to the level of modulation achieved
by AdV transduction or LPS/IFN-γ treatments alone (data
not shown, similar to [17]).
3.4. Changes in NK Cell Activation Levels and Treg Fre-
quencies after Culture with DC. We hypothesized that NK
cells would be activated (as measured by increased CD69
and CD25 expression) and that Treg frequencies might be
reduced (decreased FOXP3 expression) after interactions
with DC that were at least partially matured and that these
trends would be observed after coculture with the AdV/DC.Clinical and Developmental Immunology 5
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Figure 2: FOXP3 expression in CD4+CD3+CD25hi (Treg) cells. Phenotyping of Treg cells from patients who received the pep/DC vaccine,
showing longitudinal changes. “Pre” denotes PBMC from time point 0. “Post” denotes PBMC from postvaccine administration at time
points available. Patient A1 tested at days 35 and 56; pt B2 at d28, 56, and 112; pt B5 at d14 and 28; pt B8 and d14 and 112, pt A4 at d14. (a)
FOXP3 assessed intracellularly in CD3+CD4+CD25hi cells, showing MFI, or (b) % positivity. One-tail t-test P values are: FOXP3 MFI: pre to
post 1: 0.09, pre to post 2: 0.07, post 1 to post 2: 0.17; all other values higher and n.s. FOXP3 percent positive: pre to post 1: 0.03; pre to post
2: 0.10; all other values higher and n.s.
Monocyte-derived DC were antigen-loaded as described and
cocultured with autologous NK or CD4+ cells for 24hr or 6
days, respectively. The cells were then harvested and assessed
by FACS for phenotypic changes in speciﬁc subsets.
WeﬁrstassesseddiﬀerentAFPantigenloadingmodalities
(peptide, protein and AdV) in HD cells. Peptide pulsing
and protein-loading do not include any maturation agents
and have been observed not to alter DC phenotype in
vitro while AdV provides a partial maturation signal from
the viral transduction. While we recently investigated the
ability of AdVLacZ-transduced DC to interact with NK
cells in depth [17], the present study focused on AFP,
which has been reported to have immune suppressive
functions [38, 39]. In line with these publications, we have
observed that AdVhAFP/DC express less transmembrane
TNF than AdVLacZ/DC (L. Vujanovic and LH Butterﬁeld,
unpublished data, 2011). Here, we conﬁrmed that NK cells
coculturedwithDCupregulateCD69(increaseinMFIvalues
(Figure 3(a)) and percent positivity (not shown)). Activation
at 48hr was somewhat stronger than at 24hr (not shown).
Suﬃcient HD cells were available to also test “pre-matured”
(ﬁrst matured with IFN-γ and LPS) then AdV-transduced
DC (pmAdVhAFP/DC), which we found to more potently
activate antigen-speciﬁc CD8+ T cells than AdV/DC alone
[19]. Overall, DC transduced with AdV and/or pre-matured
and AdV-transduced were slightly more potent NK cell
activators than pep/DC or prot/DC (which were similar to
each other).
We then tested the impact of diﬀerentially antigen loaded
and matured DC on NK cell activation of HCC patients.
HCC patient CD56loCD16+ NK cells showed increased
level of activation (CD69 MFI and percent positivity)
after coincubation with DC (3/4 patients, particularly with
AdVhAFP/DC, Figure 4). However, the CD56hiCD16− NK
cells from HCC patients minimally (if at all) were activated
by the diﬀerent DC groups. Two of the patients (A3, B3)
hadCD56hiCD16− NKcellswhich(accordingtoMFIvalues)
expressedhighlevelsofCD69withoutactivation(alsohigher
than the levels detected in other patients, Figure 1(a)),
which were not further activated by DC. Overall, patient
CD56loCD16+ NK cells showed the ability to increase
in CD69 expression, particularly after coincubation with
AdV/DCascomparedtoNKalone,andotherantigen-loaded
DC produced more variable responses (Figure 4).
In order to determine any impact of DC antigen
loading on Treg expansion in vitro,H DC D 4 +Tc e l l sw e r e
cocultured for 6 days with diﬀerent DC preparations. The
pep/DC and prot/DC-stimulated groups showed increased
CD3+CD4+CD25hiFOXP3+ cells, while both AdVhAFP/DC
and pmAdVhAFP/DC-stimulated groups showed reduced
Treg frequencies and FOXP3 expression levels, compared to
baseline levels (Figure 5(a)). The opposite pattern was seen
withthetotalCD3+CD4+CD25+-activatedTcellpopulation,
indicating that the AdV/DC were superior for overall activa-
tion of CD4+ T cells (the frequency of CD3+/CD4+/CD25+
cells), without expanding FOXP3+ Treg. Using the same
experimental method, three HCC patient cells were tested
for Treg expansion. While patients A1 and B3 showed
the same pattern as the HD, HCC patient A3 showed a
diﬀerent pattern, in which no DC group showed a relative
r e d u c t i o ni nT r e gin vitro (Figures 5(b) and 5(c)). The total
CD3+CD4+CD25+-activated cells were tested in the patient
cultures, and patients A1 and B3 again showed the same
pattern as the HD, while patient A3 showed most activated
cells in the prot/DC group (Figure 5(d)).6 Clinical and Developmental Immunology
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Figure 3: CD69 expression on healthy donor CD56hi and CD56loCD16+ NK cells. Phenotyping of NK cells from HD PBMC after 48hr
coculture with diﬀerent DC groups, showing CD69 upregulation on the (a) CD56loCD16+ and (b) CD56hiCD16− subsets for three HD.
3.5. Cytokine Production. In order to characterize the DC-
lymphocyte (NK cell or CD4+ T cell) interaction envi-
ronment, cell-free supernatants were collected from the
diﬀerent HD and HCC patient cell coculture experiments.
Supernatants were tested by multiplex Luminex assay to
simultaneously assess the levels of cytokines, chemokines
and growth factors, including: GM-CSF, IFN-γ, MCP-1,
TNF-α,I L - 1 β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and IP-
10 (Figure 6 and not shown). This allowed us to examine
a functional readout of those interactions. IL-10 (produced
by suppressive cells in some settings) was largely below
the level of detection (5pg/mL). Of the “Th1/eﬀector”
cytokines and chemokines in the cocultures of CD4+ Tc e l l s
a n dD Cg r o u p s( I F N - γ, IP-10, TNF-α,I L - 2 ) ,I F N - γ was
notably higher in the two HD and one HCC (A1) coculture
of CD4+ with AdV/DC, as compared to the other DC
conditions. IP-10 also showed an increase for CD4+ Tc e l l s
stimulatedwithAdV/DC(bothHDandtwopatients:A1and
B3). Additionally, elevated IP-10 secretion was observed in
prot/DC+CD4+ T cell cultures of HD1 and all three patients,
but not to the level observed in AdV/DC cocultures. IL-2
expression, detected in all patients and only one HD, was
only minimally inﬂuenced by DC and appeared CD4+ T
cell derived (data not shown). HD IFN-γ, IP-10, and TNF-
α production was much higher than HCC patient levels
(Figure6(a)).SimilartoTNF-αand IP-10, MCP-1 expression
was greater in HD and was largely derived from immature
DC and AdV/DC (reduced in pmAdV/DC, not shown). IL-5
expression was detected in one HD and two HCC cell co-
culture of CD4+ with AdV/DC (not shown).
Coculture of NK cells with the diﬀerently antigen-loaded
DC groups yielded minimal levels of IFN-γ and TNF-α
a n dI P - 1 0w h i c hw e r el a r g e l yr e s t r i c t e dt oH Dc e l l sa n d
pmAdV/DC (Figure 6(b)). As above with the CD4+ T
cell cocultures, MCP-1 production was robust in all co-
cultures and DC derived (not shown). IL-6 was restricted
to HD and pmAdV/DC cocultures (not shown). Lastly, IL-
8 were broadly detected in most groups and were more
highly expressed in HD cultures than HCC cultures (not
shown). These data highlight important functional diﬀer-
ences between HD and HCC cells, with reduced cytokine
and chemokine production levels (but some similar trends)
among the HCC patients.
4. Discussion
Immunotherapy holds potential for treatment of hepatocel-
lular carcinoma, as few eﬀective treatments are available,
and immunotherapy vaccine strategies have largely shown
immunogenicityandlesstoxicitythancurrentchemotherapy
[40–44]. We have previously conducted vaccination clinical
trials of AFP-based vaccines for HCC, with a goal of acti-
vating the immune system against cells expressing the AFP
oncofetal antigen. Our current investigation was undertaken
with two aims. First, we sought to deﬁne phenotypic changes
in NK cells and Treg over time in the patients treated with anClinical and Developmental Immunology 7
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Figure 4: CD69expression on HCCpatient NKcells. Phenotyping of NKcells fromHCC patients after 48hr coculture with diﬀerent groups
of DC, showing CD69 upregulation on CD56hiCD16− and CD56loCD16+ subtypes, by MFI (a) and percent positivity (b).
AFP pep/DC vaccine, for the ﬁrst time. Second, we tested in
vitroresponsesofNKcellsandTregtoDCvaccinesincluding
peptide pulsed, protein-loaded, and AdV-transduced, to
determine the DC antigen loading and maturation strategy
which would promote NK activation and minimize Treg
expansion. Such data are critical for the design of next
generation DC vaccines with broad immunologic impact on
both eﬀectors and suppressive mechanisms.
An eﬀective vaccine against HCC would activate not
only tumor antigen-speciﬁc adaptive immune responses,
but also innate NK cell eﬀectors to crosstalk with DC,
promote type I responses, and potentially also directly kill
HCC cells. In addition, downregulating Treg cells would
help to minimize immunosuppression and potentially allow
enhanced antitumor eﬀector function. By testing PBMC
from the peripheral blood of patients treated with the AFP
pep/DCvaccine,wefoundevidenceforactivationofNKcells
in most patients, as shown by increase in CD69 and CD25
expression. We also found evidence for downregulation of
Treg cells in most patients, as shown by decreased FOXP3
expression in those CD4+CD25+ T cells. These results
illustratethepossibilityofrationallymodulatingtheimmune
system with DC to increase anti-HCC immunity. While
additional functional assays of NK cell killing and Treg
suppression would have strengthened our report, there were
insuﬃcient banked PBMC remaining for such assays.
In this data set, A1, A4, and B2 received 106 DC/vaccine,
and B5 and B8 received 5 × 106 DC/vaccine, and all were8 Clinical and Developmental Immunology
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stage IV (Table 1). Because A1 showed both NK cell
activation and Treg FOXP3 decrease and B2 showed neither,
there does not appear to be an overt DC dose eﬀect for
these assays. A1, B5, and B8 were heavily pretreated with a
variety of chemotherapies, while B2 had only surgery before
the DC vaccines, hence the chemotherapies do not appear to
absolutely preclude NK cell and Treg changes observed [26].
By testing in vitro responses to a variety of DC vaccines,
we were able to assess their comparative ability to stimulate
NK and Treg cells. We found that of the antigen-loading
strategies and maturation treatments we tested, AdV/DC
tended to activate NK cells more than pep/DC or prot/DC
as measured by CD69 expression. In addition, HD cells
showed downregulation of FOXP3 in CD4+CD25hi Treg cells
in the presence of AdV/DC (or pmAdV/DC) as compared
with pep/DC or prot/DC. These AdV/DC groups also
promoted increased CD3+CD4+CD25+ total activated T
cells. When testing DC groups with HCC patient cells, the
levels of NK cell activation, and diﬀerences between groups,
were weaker. While our sample size was small, these data
highlight the diﬀerent outcomes from advanced stage HCC
patients. This may also indicate an NK cell function defect
in these advanced stage patients [26], as noted by others
[22]. The Treg assessments also indicate that the general
trends observed in HD samples could be similar to HCC
patientcells,buttherewereweakerresponsesandexceptions.
Overall, these results support our conclusions from the
phenotyping of vaccinated HCC patient NK and Treg
cells, that the immune system can be favorably modulated
in multiple ways by the DC vaccines. Furthermore, theyClinical and Developmental Immunology 9
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Figure 6: Luminex results: production of chemokines and cytokines. Graphs are grouped according to scale of cytokine production and
function. (a) IFN-γ, IP-10, TNF-α, and IL-2 production after CD4+ DC coculture. (b) MCP-1 and IL-5 production after CD4+ DC co-
culture.
indicate that an AdV/DC vaccine may be superior to peptide
or protein loaded DC, although patient-speciﬁc diﬀerences
should be anticipated. In future studies, we will also test pre-
matured AdV/DC with patient-derived cells, as our banked
samples were in insuﬃcient numbers to test all DC groups in
all patients.
Cytokine production in response to DC vaccine co-
culture is a functional measure of activation of NK and
Treg cells. It was interesting to note that cytokines and
chemokines tested for by Luminex were produced more
abundantly by HD-derived cells than HCC-derived cells.
This again highlights the diﬃculty of inducing an antitumor
immune response in HCC patients, and suggests that
additional immune stimulatory and immune suppression
reducing eﬀorts may be required to promote the desired
antitumor immunity in vivo. The AFP antigen may also
play a role in these responses. We have observed similar
DC phenotypic maturation eﬀects after AdV transduction10 Clinical and Developmental Immunology
regardless of transgene; however, some speciﬁc molecular
changes have been observed. We recently demonstrated that
AdV/DC activate NK cells via transmembrane TNF and
transpresented IL-15 [17]. In order to promote that DC-NK
cell contact, we have also found that AdV/DC produce IL-8
and IP-10, which cause chemotaxis of NK cells towards DC
(Vujanovic and Butterﬁeld, submitted 2011). In this study,
we ﬁnd that the HD cocultures produced more IL-8 and IP-
10 (not shown and Figure 6) than the HCC cocultures.
We have performed additional preliminary studies com-
paring AdVLacZ and AdVhAFP in HD DC, and we ﬁnd
a reduction in DC surface transmembrane TNF expres-
sion (but similar transpresented IL-15) with AdVhAFP.
These data support the conclusion that preclinical stud-
ies to develop more eﬀective AFP-based immunotherapy
approaches for HCC should utilize patient cells, and that
additional compensatory manipulations may be required to
fully activate NK cells in addition to antigen-speciﬁc T cells,
while limiting Treg expansion.
5. Conclusions
In conclusion, we ﬁnd that DC-based vaccines can modulate
not only antigen-speciﬁc T-cell responses, but also innate
eﬀectors and counter-regulatory mechanisms. Optimal anti-
gen loading of DC and maturation signaling may allow for
development of DC vaccines which will subsequently deliver
speciﬁc signals to the broad array of tumor-reactive cells
they encounter in vivo. Immunotherapy of cancer has the
potential to improve treatment for many cancers, and this
investigation into NK cell activation and Treg modulation
induced by DC vaccines against HCC is a step forward for
designing the next generation of DC vaccines.
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